Earlier this year, it was announced that Instem was part of the Mutamind industry and academic consortium of 9 beneficiaries, funded by EMA and led by Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)1. Instem is collaborating on this 2-year research project to further investigate the mutagenicity of different classes of N-nitrosamines to distinguish highly potent from less potent carcinogens.

The project is making progress and a number of the deliverables have been recently published,2,3,4 In addition, Dr. Kevin Cross has recorded a presentation describing the project.5

If you would like to discuss this project in more detail, please get in touch with Dr. Kevin Cross (kevin.cross@instem.com).

References

  1. https://www.instem.com/news/articles/0905-instem-awarded-EMA-research-grant.php
  2. The QSAR project protocol (QSAR for Nitrosamines EUPAS 46057) is available at: https://www.encepp.eu/encepp/viewResource.htm?id=48784
  3. The in vitro project protocol (In Vitro NA Mutagenicity EUPAS 49355) is available at: https://www.encepp.eu/encepp/viewResource.htm?id=49356
  4. The endogenous formation project protocol (GITox EUPAS 49089) is available at: https://www.encepp.eu/encepp/viewResource.htm?id=49090
  5. https://get.instem.com/introducing-the-ema-mutamind-project/

Published by Glenn Myatt

Glenn J. Myatt is the co-founder of Leadscope and currently Senior Vice President, In Silico & Translational Science Solutions at Instem with over 25 years’ experience in computational chemistry/toxicology. He holds a Bachelor of Science degree in Computing, a Master of Science degree in Artificial Intelligence and a Ph.D. in Chemoinformatics. He has published 34 papers, 10 book chapters and three books.